FASN and hepatocellular carcinoma: Targeting FASN therefore promoted ubiquitinated degradation of HIF1α and inhibited SLC7A11expression, thereby increasing lipid peroxidation in resistant cells and promoting ferroptosis to resensitize HCC cells to sorafenib.